Liu Haoning, Wang Xinyi, Gong Tingting, Xu Shi, Zhang Jiachen, Yan Li, Zeng Yuyi, Yi Ming, Qian Ying
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), 51 Huayuan North Road, Haidian District, Beijing 100871, PR China.
Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, PR China.
J Anxiety Disord. 2024 Aug;106:102912. doi: 10.1016/j.janxdis.2024.102912. Epub 2024 Jul 28.
Neuromodulation treatments are novel interventions for post-traumatic stress disorder (PTSD), but their comparative effects at treatment endpoint and follow-up and the influence of moderators remain unclear. We included randomized controlled trials (RCTs) that explored neuromodulation, both as monotherapy and in combination, for treating patients with PTSD. 21 RCTs with 981 PTSD patients were included. The neuromodulation treatment was classified into nine protocols, including subtypes of transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), cervical vagal nerve stimulation (VNS), and trigeminal nerve stimulation (TNS). This Bayesian network meta-analysis demonstrated that (1) dual-tDCS (SMD = -1.30), high-frequency repetitive TMS (HF-rTMS) (SMD = -0.97), intermittent theta burst stimulation (iTBS) (SMD = -0.93), and low-frequency repetitive TMS (LF-rTMS) (SMD = -0.76) were associated with significant reductions in PTSD symptoms at the treatment endpoint, but these effects were not significant at follow-up; (2) no difference was found between any active treatment with sham controls; (3) regarding co-morbid additions, synchronized TMS (sTMS) was significantly associated with reductions of depression symptoms at treatment endpoint (SMD = -1.80) and dual-tDCS was associated with reductions in anxiety symptoms at follow-up (SMD = -1.70). Findings suggested dual-tDCS, HF-rTMS, iTBS, and LF-rTMS were effective for reducing PTSD symptoms, while their sustained efficacy was limited.
神经调节治疗是创伤后应激障碍(PTSD)的新型干预措施,但其在治疗终点和随访时的比较效果以及调节因素的影响仍不明确。我们纳入了探索神经调节作为单一疗法或联合疗法治疗PTSD患者的随机对照试验(RCT)。共纳入21项RCT,涉及981例PTSD患者。神经调节治疗分为九种方案,包括经颅磁刺激(TMS)、经颅直流电刺激(tDCS)、颈迷走神经刺激(VNS)和三叉神经刺激(TNS)的亚型。这项贝叶斯网络荟萃分析表明:(1)双靶点经颅直流电刺激(SMD = -1.30)、高频重复经颅磁刺激(HF-rTMS)(SMD = -0.97)、间歇性theta爆发刺激(iTBS)(SMD = -0.93)和低频重复经颅磁刺激(LF-rTMS)(SMD = -0.76)在治疗终点时与PTSD症状的显著减轻相关,但在随访时这些效果不显著;(2)任何积极治疗与假对照之间均未发现差异;(3)关于共病附加情况,同步经颅磁刺激(sTMS)在治疗终点时与抑郁症状减轻显著相关(SMD = -1.80),双靶点经颅直流电刺激在随访时与焦虑症状减轻相关(SMD = -1.70)。研究结果表明,双靶点经颅直流电刺激、高频重复经颅磁刺激、间歇性theta爆发刺激和低频重复经颅磁刺激对减轻PTSD症状有效,但其持续疗效有限。